OraSure Technologies (OSUR)
Market Price (8/9/2026): $4.055 | Market Cap: $279.8 MilSector: Health Care | Industry: Health Care Equipment
OraSure Technologies (OSUR)
Market Price (8/9/2026): $4.055Market Cap: $279.8 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% Low stock price volatilityVol 12M is 47% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -51%, 3Y Excs Rtn is -82% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -73 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -65% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -37%, Rev Chg QQuarterly Revenue Change % is -1.9% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% Key risksOSUR key risks include [1] the potential failure of its pivotal Sherlock CT/NG test launch and [2] declining revenues across its core businesses coupled with ongoing cash burn. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% |
| Low stock price volatilityVol 12M is 47% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -51%, 3Y Excs Rtn is -82% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -73 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -65% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -37%, Rev Chg QQuarterly Revenue Change % is -1.9% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -43% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% |
| Key risksOSUR key risks include [1] the potential failure of its pivotal Sherlock CT/NG test launch and [2] declining revenues across its core businesses coupled with ongoing cash burn. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/5/2026
OraSure Technologies (OSUR) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Positive Fiscal Q1 2026 Results and Reaffirmed Growth Outlook.
OraSure Technologies reported fiscal Q1 2026 revenue of $27.9 million on May 6, 2026, surpassing the midpoint of its guidance range. The company also achieved gross margin expansion, with GAAP gross margin at 42.3% and non-GAAP gross margin at 43.4% in fiscal Q1 2026, compared to 41.1% and 41.7% in the prior year, respectively. Management expressed confidence in accelerating growth for fiscal 2026, driven by anticipated regulatory and commercial milestones. The company also continued its share repurchase program, deploying $5 million to repurchase approximately 1.8 million shares in fiscal Q1 2026.
2. Key Regulatory Approvals for Diagnostic Products.
OraSure received significant regulatory clearances within the period, bolstering its product portfolio. On June 11, 2026, the company announced FDA clearance for its Colli-Pee Dx Urine Collection Kit, expanding patient access to testing for sexually transmitted infections. This was followed by the receipt of Emergency Use Authorization from the FDA for its second-generation Ebola test on July 21, 2026. These approvals signal progress in the company's diagnostic offerings.
Show more
OraSure Technologies (OSUR) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Positive Fiscal Q1 2026 Results and Reaffirmed Growth Outlook.
OraSure Technologies reported fiscal Q1 2026 revenue of $27.9 million on May 6, 2026, surpassing the midpoint of its guidance range. The company also achieved gross margin expansion, with GAAP gross margin at 42.3% and non-GAAP gross margin at 43.4% in fiscal Q1 2026, compared to 41.1% and 41.7% in the prior year, respectively. Management expressed confidence in accelerating growth for fiscal 2026, driven by anticipated regulatory and commercial milestones. The company also continued its share repurchase program, deploying $5 million to repurchase approximately 1.8 million shares in fiscal Q1 2026.
2. Key Regulatory Approvals for Diagnostic Products.
OraSure received significant regulatory clearances within the period, bolstering its product portfolio. On June 11, 2026, the company announced FDA clearance for its Colli-Pee Dx Urine Collection Kit, expanding patient access to testing for sexually transmitted infections. This was followed by the receipt of Emergency Use Authorization from the FDA for its second-generation Ebola test on July 21, 2026. These approvals signal progress in the company's diagnostic offerings.
Show more
Updated on 8/5/2026
OraSure Technologies (OSUR) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Positive Fiscal Q1 2026 Results and Reaffirmed Growth Outlook.
OraSure Technologies reported fiscal Q1 2026 revenue of $27.9 million on May 6, 2026, surpassing the midpoint of its guidance range. The company also achieved gross margin expansion, with GAAP gross margin at 42.3% and non-GAAP gross margin at 43.4% in fiscal Q1 2026, compared to 41.1% and 41.7% in the prior year, respectively. Management expressed confidence in accelerating growth for fiscal 2026, driven by anticipated regulatory and commercial milestones. The company also continued its share repurchase program, deploying $5 million to repurchase approximately 1.8 million shares in fiscal Q1 2026.
2. Key Regulatory Approvals for Diagnostic Products.
OraSure received significant regulatory clearances within the period, bolstering its product portfolio. On June 11, 2026, the company announced FDA clearance for its Colli-Pee Dx Urine Collection Kit, expanding patient access to testing for sexually transmitted infections. This was followed by the receipt of Emergency Use Authorization from the FDA for its second-generation Ebola test on July 21, 2026. These approvals signal progress in the company's diagnostic offerings.
3. Better-than-Expected Fiscal Q2 2026 Earnings Performance.
On August 5, 2026, OraSure reported fiscal Q2 2026 net revenue of $30.64 million, exceeding the consensus analyst estimate of $28.83 million. The company also reported a non-GAAP diluted EPS of -$0.20, which was better than the analyst estimate of -$0.21. While GAAP diluted EPS improved to $0.09 primarily due to a $22.6 million reduction in acquisition-related contingent consideration, the revenue beat and improved non-GAAP EPS contributed to positive market sentiment.
4. Ongoing Strategic Transformation and Cost Efficiencies.
The company's continued strategic transformation efforts, including substantial cost-cutting measures and a focus on high-value growth markets, have likely supported investor confidence. OraSure had previously announced initiatives such as a 37% reduction in SG&A expenses since 2022 and a approximately 40% reduction in its global workforce since late 2022. These operational improvements aim to streamline the business and drive long-term value, as evidenced by a 10% sequential revenue increase in the core business in fiscal Q2 2026.
Show less
OraSure Technologies (OSUR) stock has gained about 35% since 4/30/2026 because of the following key factors:
1. Positive Fiscal Q1 2026 Results and Reaffirmed Growth Outlook.
OraSure Technologies reported fiscal Q1 2026 revenue of $27.9 million on May 6, 2026, surpassing the midpoint of its guidance range. The company also achieved gross margin expansion, with GAAP gross margin at 42.3% and non-GAAP gross margin at 43.4% in fiscal Q1 2026, compared to 41.1% and 41.7% in the prior year, respectively. Management expressed confidence in accelerating growth for fiscal 2026, driven by anticipated regulatory and commercial milestones. The company also continued its share repurchase program, deploying $5 million to repurchase approximately 1.8 million shares in fiscal Q1 2026.
2. Key Regulatory Approvals for Diagnostic Products.
OraSure received significant regulatory clearances within the period, bolstering its product portfolio. On June 11, 2026, the company announced FDA clearance for its Colli-Pee Dx Urine Collection Kit, expanding patient access to testing for sexually transmitted infections. This was followed by the receipt of Emergency Use Authorization from the FDA for its second-generation Ebola test on July 21, 2026. These approvals signal progress in the company's diagnostic offerings.
3. Better-than-Expected Fiscal Q2 2026 Earnings Performance.
On August 5, 2026, OraSure reported fiscal Q2 2026 net revenue of $30.64 million, exceeding the consensus analyst estimate of $28.83 million. The company also reported a non-GAAP diluted EPS of -$0.20, which was better than the analyst estimate of -$0.21. While GAAP diluted EPS improved to $0.09 primarily due to a $22.6 million reduction in acquisition-related contingent consideration, the revenue beat and improved non-GAAP EPS contributed to positive market sentiment.
4. Ongoing Strategic Transformation and Cost Efficiencies.
The company's continued strategic transformation efforts, including substantial cost-cutting measures and a focus on high-value growth markets, have likely supported investor confidence. OraSure had previously announced initiatives such as a 37% reduction in SG&A expenses since 2022 and a approximately 40% reduction in its global workforce since late 2022. These operational improvements aim to streamline the business and drive long-term value, as evidenced by a 10% sequential revenue increase in the core business in fiscal Q2 2026.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 33.2% change in OSUR stock from 4/30/2026 to 8/8/2026 was primarily driven by a 31.5% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.04 | 4.05 | 33.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 115 | 112 | -2.3% |
| P/S Multiple | 1.9 | 2.5 | 31.5% |
| Shares Outstanding (Mil) | 72 | 69 | 3.7% |
| Cumulative Contribution | 33.2% |
Market Drivers
4/30/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| OSUR | 33.2% | |
| Market (SPY) | 7.6% | 12.9% |
| Sector (XLV) | 13.5% | 21.5% |
Fundamental Drivers
The 45.2% change in OSUR stock from 1/31/2026 to 8/8/2026 was primarily driven by a 53.4% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.79 | 4.05 | 45.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 126 | 112 | -10.6% |
| P/S Multiple | 1.6 | 2.5 | 53.4% |
| Shares Outstanding (Mil) | 73 | 69 | 5.8% |
| Cumulative Contribution | 45.2% |
Market Drivers
1/31/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| OSUR | 45.2% | |
| Market (SPY) | 12.1% | 19.2% |
| Sector (XLV) | 7.5% | 26.5% |
Fundamental Drivers
The 27.4% change in OSUR stock from 7/31/2025 to 8/8/2026 was primarily driven by a 68.8% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.18 | 4.05 | 27.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 162 | 112 | -30.4% |
| P/S Multiple | 1.5 | 2.5 | 68.8% |
| Shares Outstanding (Mil) | 75 | 69 | 8.5% |
| Cumulative Contribution | 27.4% |
Market Drivers
7/31/2025 to 8/8/2026| Return | Correlation | |
|---|---|---|
| OSUR | 27.4% | |
| Market (SPY) | 23.4% | 29.0% |
| Sector (XLV) | 28.7% | 28.2% |
Fundamental Drivers
The -14.2% change in OSUR stock from 7/31/2023 to 8/8/2026 was primarily driven by a -76.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312023 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.72 | 4.05 | -14.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 475 | 112 | -76.3% |
| P/S Multiple | 0.7 | 2.5 | 242.0% |
| Shares Outstanding (Mil) | 73 | 69 | 6.0% |
| Cumulative Contribution | -14.2% |
Market Drivers
7/31/2023 to 8/8/2026| Return | Correlation | |
|---|---|---|
| OSUR | -14.2% | |
| Market (SPY) | 74.9% | 30.4% |
| Sector (XLV) | 29.3% | 30.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OSUR Return | -18% | -45% | 70% | -56% | -33% | 65% | -62% |
| Peers Return | 30% | -10% | 2% | -4% | 1% | 14% | 33% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| OSUR Win Rate | 50% | 42% | 50% | 8% | 42% | 62% | |
| Peers Win Rate | 68% | 47% | 57% | 53% | 48% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OSUR Max Drawdown | -46% | -71% | -40% | -57% | -49% | -16% | |
| Peers Max Drawdown | -18% | -39% | -35% | -39% | -30% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EW, UFPT, ATRC, IART, ABT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)
How Low Can It Go
| Event | OSUR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -38.3% | -18.8% |
| % Gain to Breakeven | 62.1% | 23.1% |
| Time to Breakeven | 375 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -21.8% | -33.7% |
| % Gain to Breakeven | 27.8% | 50.9% |
| Time to Breakeven | 1 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -32.2% | -19.2% |
| % Gain to Breakeven | 47.6% | 23.8% |
| Time to Breakeven | 493 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.9% | -3.7% |
| % Gain to Breakeven | 14.8% | 3.9% |
| Time to Breakeven | 7 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -22.4% | -12.2% |
| % Gain to Breakeven | 28.8% | 13.9% |
| Time to Breakeven | 37 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -46.7% | -6.8% |
| % Gain to Breakeven | 87.6% | 7.3% |
| Time to Breakeven | 334 days | 15 days |
In The Past
OraSure Technologies's stock fell -38.3% during the 2025 US Tariff Shock. Such a loss loss requires a 62.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | OSUR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -38.3% | -18.8% |
| % Gain to Breakeven | 62.1% | 23.1% |
| Time to Breakeven | 375 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -21.8% | -33.7% |
| % Gain to Breakeven | 27.8% | 50.9% |
| Time to Breakeven | 1 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -32.2% | -19.2% |
| % Gain to Breakeven | 47.6% | 23.8% |
| Time to Breakeven | 493 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -22.4% | -12.2% |
| % Gain to Breakeven | 28.8% | 13.9% |
| Time to Breakeven | 37 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -46.7% | -6.8% |
| % Gain to Breakeven | 87.6% | 7.3% |
| Time to Breakeven | 334 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -34.9% | -17.9% |
| % Gain to Breakeven | 53.6% | 21.8% |
| Time to Breakeven | 105 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -33.1% | -15.4% |
| % Gain to Breakeven | 49.4% | 18.2% |
| Time to Breakeven | 210 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -75.7% | -53.4% |
| % Gain to Breakeven | 311.1% | 114.4% |
| Time to Breakeven | 849 days | 1085 days |
In The Past
OraSure Technologies's stock fell -38.3% during the 2025 US Tariff Shock. Such a loss loss requires a 62.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About OraSure Technologies (OSUR)
OraSure Technologies (OSUR) is a healthcare company focused on developing, manufacturing, and selling a range of diagnostic products and specimen collection devices. The company operates through two primary business segments: Diagnostics and Molecular Solutions, addressing both rapid point-of-care testing needs and advanced molecular analysis.
In its Diagnostics segment, OraSure offers various rapid tests for infectious diseases, including the InteliSwab COVID-19 rapid tests and the well-known OraQuick line of HIV tests (including in-home and self-test versions), as well as tests for HCV and Ebola. This segment also provides drug and alcohol testing systems like Intercept and Q.E.D. saliva alcohol tests, alongside related collection devices and immunoassay reagents.
The Molecular Solutions segment specializes in products for collecting, stabilizing, and transporting biological samples, particularly for genetic and microbiome analysis. Key offerings include genomic collection products under the Oragene and ORAcollect brands, devices for COVID-19 molecular testing, and the Colli-Pee urine collection device. This segment also provides GenoFIND genomics laboratory services and kits for molecular testing in diverse applications such as academic research, ancestry, disease risk management, and animal testing. OraSure serves a wide array of customers, including clinical laboratories, hospitals, public health organizations, government agencies, commercial entities, and researchers.
AI Analysis | Feedback
Here are 1-2 brief analogies for OraSure Technologies (OSUR):
1. OraSure is like a specialized Abbott Laboratories, focusing on rapid, non-invasive diagnostic tests such as at-home HIV or COVID tests using oral fluid.
2. They also develop and manufacture the specialized sample collection kits essential for genetic and molecular testing, similar to the underlying technology that powers consumer genetic services like 23andMe or Ancestry.com.
AI Analysis | Feedback
- InteliSwab COVID-19 Rapid Tests: A line of rapid diagnostic tests for detecting COVID-19.
- OraQuick HIV Tests: Includes rapid, in-home, and self-test options for detecting HIV antibodies.
- OraQuick HCV Rapid Antibody Test: A rapid diagnostic test for detecting Hepatitis C virus antibodies.
- OraQuick Ebola Rapid Antigen Test: A rapid diagnostic test for detecting Ebola virus antigens.
- OraSure Oral Fluid Collection Devices: Devices primarily used for collecting oral fluid specimens for diagnostic testing.
- Intercept Drug Testing Systems: Comprehensive systems designed for drug screening and testing.
- Q.E.D. Saliva Alcohol Test: A rapid, convenient test for detecting alcohol levels in saliva.
- Oragene and ORAcollect Genomic Collection Products: Products, including devices and kits, for the collection, stabilization, transport, and storage of genetic material for molecular testing.
- Microbiome Collection Products: Devices specifically designed for collecting microbiome samples for research and diagnostic purposes.
- GenoFIND Genomics Laboratory Services: Laboratory services that provide genomics testing and analysis.
- Colli-Pee Collection Device: A specialized device for the volumetric collection of first void urine samples.
- Immunoassay Tests and Reagents: A range of diagnostic tests and associated reagents utilizing immunoassay technology.
AI Analysis | Feedback
OraSure Technologies (OSUR) primarily sells its products to a variety of organizations and entities rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:
- Healthcare Providers and Organizations: This broad category includes clinical laboratories, hospitals, clinics, physicians' offices, community-based organizations, and other public health organizations that utilize OraSure's diagnostic tests and collection devices.
- Government Agencies: Federal, state, and local government agencies are customers, particularly for public health initiatives (e.g., HIV, COVID-19 testing) and potentially for other applications like drug testing.
- Distributors: OraSure leverages distributors to market and sell its products, expanding its reach to various end-users.
- Commercial and Industrial Entities: These customers utilize products such as OraSure's drug testing systems (e.g., Intercept drug testing systems, Q.E.D. saliva alcohol test) and genomic sample collection kits for various applications including academic research, ancestry, disease risk management, and animal testing.
AI Analysis | Feedback
null
AI Analysis | Feedback
Carrie Eglinton Manner President and Chief Executive Officer
Carrie Eglinton Manner was appointed President and Chief Executive Officer of OraSure Technologies in June 2022. She also joined the OraSure Board of Directors. Prior to joining OraSure, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostics Clinical Solutions, at Quest Diagnostics, where she was responsible for bringing innovative diagnostic solutions to market across various health areas. Before her tenure at Quest Diagnostics, she spent 20 years in various leadership roles with increasing responsibility, including multiple distinct business units with global engineering and manufacturing responsibilities at GE Healthcare, a division of General Electric (GE).
Kenneth J. McGrath Chief Financial Officer
Kenneth J. McGrath was named Chief Financial Officer in August 2022. In this role, he is responsible for overseeing finance, accounting, tax, and information technology. Before joining OraSure, Mr. McGrath spent eight years at Quest Diagnostics, most recently serving as Vice President in Finance, where he led an organization responsible for over $7 billion in revenue. He also helped build Quest's Advanced Diagnostics business. Prior to his time at Quest, Mr. McGrath held various leadership positions in finance operating roles at Johnson & Johnson, Inc., and began his career at Ford Motor Company.
Michele Anthony Senior Vice President, Controller, and Chief Accounting Officer
Michele Anthony serves as the Senior Vice President, Controller, and Chief Accounting Officer at OraSure Technologies.
David Rappaport Senior Vice President, Corporate Development, Strategy and Integration
David Rappaport, CFA, holds the position of Senior Vice President, Corporate Development, Strategy and Integration at OraSure Technologies.
Zachary Wert Senior Vice President, Global Operations
Zachary Wert is the Senior Vice President, Global Operations at OraSure Technologies.
AI Analysis | Feedback
Key Business Risks for OraSure Technologies (OSUR)
- Declining demand for COVID-19 related products: OraSure Technologies has several InteliSwab COVID-19 rapid tests and COVID-19 molecular testing collection devices listed among its principal products. As the global COVID-19 pandemic recedes, vaccination rates increase, and treatment options become more prevalent, the demand for these diagnostic and collection products could significantly decrease. This potential decline in sales would directly impact the company's revenue and profitability.
- Intense competition in diagnostic and molecular solutions markets: The diagnostic and molecular solutions industries are highly competitive. OraSure Technologies develops and sells a wide range of products, including HIV tests, HCV tests, drug testing systems, and genomic and microbiome collection devices. The company faces significant competition from numerous established players and new entrants, which could lead to pricing pressures, erosion of market share, and challenges in successfully developing and launching new products.
- Dependence on public health initiatives and government funding: Many of OraSure's products, such as its OraQuick HIV tests, OraQuick Ebola rapid antigen test, and certain COVID-19 related products, are marketed to clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, and government agencies. The demand for these products is often influenced by government funding levels, shifts in public health priorities, and procurement policies, making the company susceptible to changes in these areas.
AI Analysis | Feedback
The clear emerging threat for OraSure Technologies (OSUR) is the diminishing market demand for its principal InteliSwab COVID-19 rapid test products. As the global pandemic environment evolves, with increasing vaccination rates and a transition towards endemic status for COVID-19, the demand for rapid diagnostic tests is expected to significantly decline, impacting a core revenue stream for the company.
AI Analysis | Feedback
OraSure Technologies (OSUR) operates in several significant addressable markets with its diverse range of diagnostic and specimen collection products. The market sizes for their main products and services are outlined below:
InteliSwab COVID-19 Rapid Test
- The global COVID Rapid Diagnostic Test Market was estimated at USD 10.55 billion in 2025 and is projected to decline to USD 5.92 billion by 2030.
- Alternatively, the global COVID-19 Rapid Antigen Test Market was valued at USD 6.03 billion in 2024 and is expected to grow to approximately USD 10.13 billion by 2032.
- North America holds a significant share of the global COVID Rapid Diagnostic Test Market. The Asia Pacific region dominated the COVID-19 rapid antigen test market, accounting for 37.0% of total revenue in 2022 and 39.5% in 2023.
OraQuick HIV Tests (Rapid HIV, In-Home, Self-Test)
- The global HIV AIDS Testing Market is anticipated to be valued at US$ 4.1 billion in 2025 and is projected to reach US$ 6.6 billion by 2032.
- Other estimates place the global HIV diagnostics market at USD 1.34 billion in 2025, rising to approximately USD 2.24 billion by 2035. Another report valued the global HIV/AIDS diagnostics market at USD 4,583.90 million in 2023, with a projection to reach USD 10,897.40 million by 2032.
- North America is a leading market, holding approximately 40% of the global HIV/AIDS diagnostics market share in 2023 and projected to reach USD 2,228.61 million by 2030 for HIV diagnostics.
- The demand for home-based HIV testing kits is increasing globally.
OraQuick HCV Rapid Antibody Test
- The global Hepatitis C Testing Market was valued at USD 1.5 billion in 2023 and is projected to reach USD 2.6 billion by 2035.
- Another source projects the global hepatitis C virus (HCV) testing market to grow from USD 0.9 billion in 2025 to USD 1.4 billion by 2035.
- North America was the largest shareholder in the global hepatitis C testing market in 2023. The United States specifically held more than 29.5% of the global market share in 2023.
Intercept Drug Testing Systems (Oral Fluid Drug Testing)
- The global rapid oral fluid screening device market was valued at USD 14.13 billion in 2025 and is expected to reach USD 44.87 billion by 2033.
- Another estimate for the global oral fluid samples drug testing market size was US$ 2,267.9 million in 2024, projected to grow to US$ 3,497.8 million by 2030.
- The global oral fluid drug test system market value is expected to rise from USD 0.48 billion in 2026 to USD 1.16 billion by 2035.
- North America dominated the rapid oral fluid screening device market with a 38.76% revenue share in 2025 and accounted for approximately 40% of global oral fluid drug test utilization in 2024.
Q.E.D. Saliva Alcohol Test
- The global Saliva Alcohol Tests Market was valued at USD 800 million in 2024 and is expected to grow to USD 1,500 million by 2035.
- North America's saliva alcohol tests market was valued at USD 280 million in 2024 and is expected to reach USD 542 million in 2035.
Genomic Products (Oragene, ORAcollect brands for DNA/RNA collection, OMNIgene, RAL collection devices) and GenoFIND Genomics Laboratory Services
- The global genomics services market size was valued at USD 9.80 billion in 2025 and is projected to grow to USD 30.85 billion by 2034. Another report estimates the market at USD 7.94 billion in 2025, reaching USD 25.18 billion by 2035.
- North America held the largest revenue share, accounting for 39.68% in 2025 and over 40.12% in 2025. The U.S. genomics services market was estimated at USD 3.18 billion in 2025.
- The global DNA and RNA sample preparation market was valued at USD 1,600 million in 2022 and is projected to reach USD 4,806 million by 2030. Another source valued the DNA and RNA Sample Preparation Market at USD 2,262.2 million in 2025, reaching USD 3,356.8 million in 2032.
Microbiome Collection Products
- The global microbiome sequencing services market size was estimated at USD 1.37 billion in 2022 and is projected to reach USD 3.10 billion by 2030. Other estimates place it at USD 1,508.9 million in 2023, reaching USD 3,106.2 million by 2030, and USD 3,048.0 million in 2025, projected to reach USD 12,128.4 million by 2034.
- North America dominated this market with a revenue share of 47.85% in 2022 and 47.7% in 2023.
Colli-Pee Collection Device (Urine Collection Devices)
- The global urine collection devices market is estimated to be valued between USD 3.08 billion and USD 3.2 billion in 2025, with projections to reach between USD 4.57 billion by 2032 and USD 5.3 billion by 2035.
- North America is a significant region, dominating the global urine collection devices market with an estimated market share of 41.7% in 2025.
Kits for Genetic Material Collection (Consumer Genomics/Ancestry, Disease Risk Management, Lifestyle, Animal Testing)
- The global consumer genomics market size was estimated at USD 7.4 billion in 2024 and is expected to grow from USD 8.3 billion in 2025 to USD 27.1 billion by 2034.
- Other reports estimate the global consumer genomics market size at USD 2.54 billion in 2025, projected to reach around USD 18.83 billion by 2034, or USD 2.54 billion in 2025, reaching USD 21.23 billion by 2033.
- North America held 42% of the global market share in 2024 and dominated the market with more than 37% of revenue share in 2024.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for OraSure Technologies (OSUR) over the next 2-3 years:
- Launch of New Diagnostic Products: OraSure Technologies anticipates revenue growth from new product launches, specifically a rapid molecular self-test for chlamydia and gonorrhea (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections (STIs). Both products were submitted to the FDA in December (likely 2025) and are expected to drive revenue in the second half of 2026.
- International Expansion and Partnerships: The company is expanding its global footprint, notably with the launch of the OraQuick HIV Self-Test in Canada and strong demand for the SickleScan rapid point-of-need test (acquired through BioMedomics) in Africa and Latin America. Efforts to establish closer relationships with existing distribution partners and "nearshoring" for local manufacturing and assembly in Africa are also expected to contribute to growth.
- Growth in Core Diagnostic Products: OraSure's international HIV business demonstrated strong order trends in the fourth quarter of 2024, achieving a record year for revenue in that segment. The "Together Take Me Home" program, which distributes HIV at-home test kits, has also been renewed for a fourth year, contributing to continued sales in this area.
- Expansion of Sample Management Solutions: While facing some disruption from a large consumer genetics customer, the remaining customer base within the Sample Management Solutions segment has shown year-over-year growth. The company also expects modest revenue contributions from academic and government sectors as NIH funding stabilizes, and from its blood proteomic solution launched in mid-2025.
AI Analysis | Feedback
Capital Allocation Decisions for OraSure Technologies (OSUR)
Share Repurchases
- OraSure Technologies authorized a share repurchase program of up to $40 million of its common stock over 24 months, effective March 24, 2025.
- In the third quarter of 2025, the company repurchased approximately 1.5 million shares for $5 million.
- For the full year 2025, OraSure repurchased 5.3 million shares, returning $15 million in capital to shareholders.
Share Issuance
- OraSure Technologies reported stock-based compensation of $10.147 million in 2025 and $11.920 million in 2024.
- The company issued $10.729 million in stock-based compensation in 2023 and $11.622 million in 2022.
- As of July 31, 2025, the company had 73,136,987 shares of common stock outstanding.
Inbound Investments
- In July 2025, OraSure's board rejected an unsolicited all-cash offer from healthcare entrepreneur Ron Zwanziger to acquire the company at $3.50 to $4.00 per share.
- The company received $24.4 million in the fourth quarter of 2023 and $60.331 million in 2022 from the U.S. government related to manufacturing expansion contracts.
Outbound Investments
- OraSure Technologies signed a definitive agreement on November 5, 2025, and completed the acquisition of BioMedomics in November 2025 for an upfront cash payment of $4 million, with potential contingent consideration.
- In December 2024, OraSure acquired Sherlock Biosciences, a diagnostic platform provider for DNA and RNA detection.
- On March 27, 2025, OraSure divested certain assets of its substance abuse testing business line to Premier Biotech.
Capital Expenditures
- Capital expenditures totaled $4.197 million in 2025 and $3.797 million in 2024.
- The company reported capital expenditures of $10.303 million in 2023 and $63.909 million in 2022.
- Investments in the Sherlock platform, clinical trials for its molecular CT/NG test, and other innovation projects contributed to negative operating cash flow in the third and fourth quarters of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| OraSure Technologies Earnings Notes | 12/16/2025 | |
| OraSure Technologies Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 65.56 |
| Mkt Cap | 2.2 |
| Rev LTM | 1,140 |
| Op Inc LTM | 81 |
| FCF LTM | 57 |
| FCF 3Y Avg | 36 |
| CFO LTM | 78 |
| CFO 3Y Avg | 84 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.7% |
| Rev Chg 3Y Avg | 9.1% |
| Rev Chg Q | 12.9% |
| QoQ Delta Rev Chg LTM | 3.2% |
| Op Inc Chg LTM | 6.9% |
| Op Inc Chg 3Y Avg | 14.1% |
| Op Mgn LTM | 9.6% |
| Op Mgn 3Y Avg | 9.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 11.4% |
| CFO/Rev 3Y Avg | 9.5% |
| FCF/Rev LTM | 9.4% |
| FCF/Rev 3Y Avg | 6.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Human immunodeficiency virus (HIV) | 50 | 61 | 61 | 39 | 42 |
| Sample Management Solutions | 38 | 51 | 54 | 63 | 73 |
| Hepatitis C virus (HCV) | 14 | 14 | 13 | 13 | 12 |
| Non-product and services revenues | 6 | 1 | 3 | 9 | 7 |
| Other product and service revenues | 5 | 4 | 2 | 2 | 2 |
| Risk assessment testing | 2 | 8 | 10 | 10 | 10 |
| Coronavirus disease 2019 (COVID-19) | 1 | 45 | 258 | 243 | 77 |
| Molecular Services | 0 | 2 | 4 | 7 | 12 |
| Total | 115 | 186 | 405 | 387 | 234 |
| $ Mil | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Diagnostics | -1 | -57 | -43 | 0 | -20 |
| Molecular Solutions | -22 | 47 | 38 | 18 | 49 |
| Total | -23 | -10 | -5 | 19 | 28 |
| $ Mil | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Diagnostics | 280 | 210 | 243 | 164 | 190 |
| Molecular Solutions | 165 | 251 | 212 | 185 | 125 |
| Total | 445 | 461 | 454 | 349 | 316 |
Price Behavior
Price Behavior
| Market Price | $4.05 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 03/17/1992 | |
| Distance from 52W High | -10.0% | |
| 50 Days | 200 Days | |
| DMA Price | $4.14 | $3.14 |
| DMA Trend | up | up |
| Distance from DMA | -2.2% | 29.0% |
| 3M | 1YR | |
| Volatility | 50.8% | 47.4% |
| Downside Capture | 43.95 | 80.85 |
| Upside Capture | 155.90 | 105.24 |
| Correlation (SPY) | 14.7% | 28.9% |
OSUR Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.23 | 0.37 | 0.43 | 0.63 | 1.08 | 1.01 |
| Up Beta | 0.39 | 0.66 | -0.22 | 0.58 | 1.03 | 1.05 |
| Down Beta | -1.77 | 0.35 | 0.42 | 0.46 | 1.53 | 1.13 |
| Up Capture | 12% | 10% | 129% | 107% | 95% | 54% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 19 | 31 | 59 | 122 | 354 |
| Down Capture | 159% | 49% | -2% | 38% | 90% | 101% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 23 | 29 | 59 | 117 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | 42.1% | 47.4% | 0.88 | - |
| Sector ETF (XLV) | 28.7% | 15.5% | 1.42 | 27.0% |
| Equity (SPY) | 23.3% | 12.8% | 1.36 | 28.8% |
| Gold (GLD) | 28.5% | 28.4% | 0.87 | 9.0% |
| Commodities (DBC) | 32.9% | 19.8% | 1.32 | -8.7% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 14.0% |
| Bitcoin (BTCUSD) | -43.7% | 43.0% | -1.21 | 9.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | -19.2% | 54.6% | -0.19 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 31.6% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | 32.9% |
| Gold (GLD) | 18.6% | 18.6% | 0.81 | 4.4% |
| Commodities (DBC) | 8.2% | 19.6% | 0.31 | 2.9% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 27.7% |
| Bitcoin (BTCUSD) | 9.0% | 53.0% | 0.36 | 14.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OSUR | |
|---|---|---|---|---|
| OSUR | -4.7% | 56.6% | 0.15 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 31.4% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 29.1% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 1.7% |
| Commodities (DBC) | 7.4% | 18.0% | 0.33 | 4.5% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 18.9% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -3.6% | ||
| 5/6/2026 | 4.3% | 1.3% | 34.7% |
| 2/25/2026 | 10.0% | 7.5% | 9.6% |
| 11/5/2025 | -6.6% | -3.9% | -4.3% |
| 8/5/2025 | -8.5% | -10.3% | 1.0% |
| 5/7/2025 | -6.8% | -10.8% | 3.6% |
| 2/25/2025 | -23.5% | -15.7% | -15.2% |
| 11/6/2024 | -3.6% | -8.0% | -11.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 12 |
| # Negative | 12 | 14 | 12 |
| Median Positive | 4.8% | 12.9% | 14.7% |
| Median Negative | -6.7% | -9.8% | -14.0% |
| Max Positive | 32.3% | 40.5% | 43.4% |
| Max Negative | -33.1% | -29.6% | -45.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | -3.6% | ||
| 5/6/2026 | 4.3% | 1.3% | 34.7% |
| 2/25/2026 | 10.0% | 7.5% | 9.6% |
| 11/5/2025 | -6.6% | -3.9% | -4.3% |
| 8/5/2025 | -8.5% | -10.3% | 1.0% |
| 5/7/2025 | -6.8% | -10.8% | 3.6% |
| 2/25/2025 | -23.5% | -15.7% | -15.2% |
| 11/6/2024 | -3.6% | -8.0% | -11.1% |
| 8/6/2024 | 0.5% | -3.7% | 3.5% |
| 5/8/2024 | -5.0% | 1.4% | -11.7% |
| 2/27/2024 | 10.0% | -0.4% | -12.7% |
| 11/7/2023 | 2.9% | 18.3% | 19.8% |
| 8/3/2023 | 32.3% | 40.5% | 43.4% |
| 5/10/2023 | 4.8% | -23.0% | -25.4% |
| 2/14/2023 | 12.2% | 23.1% | 32.3% |
| 11/8/2022 | 3.5% | 24.2% | 21.8% |
| 8/9/2022 | 32.3% | 37.9% | 22.6% |
| 5/10/2022 | -2.5% | -0.8% | -45.2% |
| 2/23/2022 | 3.3% | 2.3% | -7.5% |
| 11/3/2021 | -7.4% | -14.7% | -21.9% |
| 8/3/2021 | -3.5% | -8.8% | -9.9% |
| 5/5/2021 | 7.9% | 2.9% | 3.0% |
| 3/1/2021 | 0.2% | -13.8% | 0.5% |
| 11/4/2020 | -14.5% | -9.3% | -19.6% |
| 8/5/2020 | -33.1% | -29.6% | -45.2% |
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 12 |
| # Negative | 12 | 14 | 12 |
| Median Positive | 4.8% | 12.9% | 14.7% |
| Median Negative | -6.7% | -9.8% | -14.0% |
| Max Positive | 32.3% | 40.5% | 43.4% |
| Max Negative | -33.1% | -29.6% | -45.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/07/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/02/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
Recent Forward Guidance
Updated 8/6/2026Latest: Q2 2026 Earnings Reported 8/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Revenue | 29.50 Mil | 31.00 Mil | 32.50 Mil | 8.8% | Higher New | Guidance: 28.50 Mil for Q2 2026 | |
Prior: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | 27.00 Mil | 28.50 Mil | 30.00 Mil | 3.6% | Higher New | Guidance: 27.50 Mil for Q1 2026 | |
Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 26.00 Mil | 27.50 Mil | 29.00 Mil | 3.8% | Higher New | Guidance: 26.50 Mil for Q4 2025 | |
Q3 2025 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Total Revenue | 25.00 Mil | 26.50 Mil | 28.00 Mil | ||||
| Q4 2025 COVID-19 Testing Revenues | 0.10 Mil | ||||||
Insider Activity
Updated 6/5/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 2.99 | 25,000 | 74,750 | 339,251 | Form | |
| 2 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 3.02 | 25,000 | 75,500 | 267,155 | Form | |
| 3 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 2.98 | 25,000 | 74,500 | 189,117 | Form | |
| 4 | McGrath, Kenneth J | Chief Financial Officer | Direct | Buy | 3232026 | 2.93 | 32,300 | 94,600 | 1,726,709 | Form |
| 5 | Eglinton, Manner Carrie | President & CEO | Direct | Buy | 3232026 | 2.93 | 32,300 | 94,597 | 6,416,413 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 2.99 | 25,000 | 74,750 | 339,251 | Form | |
| 2 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 3.02 | 25,000 | 75,500 | 267,155 | Form | |
| 3 | Boyd, Steven Kyle | Direct | Buy | 5142026 | 2.98 | 25,000 | 74,500 | 189,117 | Form | |
| 4 | McGrath, Kenneth J | Chief Financial Officer | Direct | Buy | 3232026 | 2.93 | 32,300 | 94,600 | 1,726,709 | Form |
| 5 | Eglinton, Manner Carrie | President & CEO | Direct | Buy | 3232026 | 2.93 | 32,300 | 94,597 | 6,416,413 | Form |
| 6 | McGrath, Kenneth J | Chief Financial Officer | Direct | Buy | 3162026 | 3.00 | 22,021 | 66,030 | 1,670,950 | Form |
| 7 | Eglinton, Manner Carrie | President & CEO | Direct | Buy | 3162026 | 3.00 | 22,022 | 66,033 | 6,472,484 | Form |
| 8 | Gagliano, Nancy J | Direct | Buy | 12022025 | 2.37 | 2,100 | 4,982 | 380,171 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/8/2026